| Immunoglobulin A levels and its correlation with neutrophil-to-lymphocyte ratio as inflammatory biomarkers for dry eye disease in type 2 diabetes: a retrospective study. | Immunoglobulin A levels and its correlation with neutrophil-to-lymphocyte ratio as inflammatory biomarkers for dry eye disease in type 2 diabetes: a retrospective study.
Alhalwani AY, Abudawood K, Qadizadah ABEA, Jambi S, Sannan NS., Free PMC Article | 08/4/2023 |
| Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. | Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.
Leung I, Templeton ML, Lo Y, Rajan A, Stull SM, Garrison SM, Salter AI, Smythe KS, Correnti CE, Srivastava S, Yeung CCS, Riddell SR., Free PMC Article | 06/22/2023 |
| Galactose-deficient IgA1 Is Involved in IgA Deposition in Renal Grafts Biopsied One Hour after Kidney Transplantation. | Galactose-deficient IgA1 Is Involved in IgA Deposition in Renal Grafts Biopsied One Hour after Kidney Transplantation.
Kuroyanagi Y, Takeda A, Kinashi H, Kuroyanagi Y, Murata M, Futamura K, Goto N, Watarai Y, Ishimoto T, Morozumi K, Ito Y., Free PMC Article | 06/2/2023 |
| Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19. | Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19.
Ameratunga R, Leung E, Woon ST, Lea E, Allan C, Chan L, Steele R, Lehnert K, Longhurst H., Free PMC Article | 01/14/2023 |
| Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. | Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH., Free PMC Article | 12/3/2022 |
| CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia. | CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.
Lenk L, Carlet M, Vogiatzi F, Spory L, Winterberg D, Cousins A, Vossen-Gajcy M, Ibruli O, Vokuhl C, Cario G, El Ayoubi O, Kramer L, Ritgen M, Brüggemann M, Häsler R, Schrappe M, Fuhrmann S, Halsey C, Jeremias I, Hobeika E, Jumaa H, Alsadeq A, Schewe DM., Free PMC Article | 07/3/2021 |
| Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma. | Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma.
Sakatani A, Igawa T, Okatani T, Fujihara M, Asaoku H, Sato Y, Yoshino T., Free PMC Article | 01/23/2021 |
| Aberrant CD79a and/or PAX5 expression can be found in Acute Myelogenous Leukemia cases with RUNX1 mutations even without the translocation t(8; 21). | RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.
Menter T, Lundberg P, Wenzel F, Dirks J, Fernandez P, Friess D, Dirnhofer S, Tzankov A. | 08/10/2019 |
| The incidence of MYD88 and CD79B mutations in patients with CD5(+) DLBCL is lower than that in patients with DLBCL-SS, suggesting that CD5(+) DLBCL is not the same disease as DLBCL-SS in terms of gene mutation status. | MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, Ono R, Nosaka T, Tanaka K, Katayama N. | 06/3/2017 |
| Data show that Bruton tyrosine kinase (BTK)inhibitor Ibrutinib augments MALT lymphoma associated translocation protein (MALT1) inhibition by S-Mepazine in CD79 antigen mutant activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL). | Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D, Bognar M, Eitelhuber AC, Kutzner K, Vincendeau M, Krappmann D., Free PMC Article | 10/1/2016 |
| Phosphorylation of CD79a causes a decrease in helical propensity in the C-terminal region, for CD79b, the opposite was observed and phosphorylation resulted in an increase of helical propensity in the C-terminal part. | Tyrosine phosphorylation within the intrinsically disordered cytosolic domains of the B-cell receptor: an NMR-based structural analysis.
Rosenlöw J, Isaksson L, Mayzel M, Lengqvist J, Orekhov VY., Free PMC Article | 01/24/2015 |
| High intensity of caries is associated with increased levels of some salivary components - sIgA, histatin-5 and lactoperoxidase. | The assessment of sIgA, histatin-5, and lactoperoxidase levels in saliva of adolescents with dental caries.
Gornowicz A, Tokajuk G, Bielawska A, Maciorkowska E, Jabłoński R, Wójcicka A, Bielawski K., Free PMC Article | 12/20/2014 |
| CD79a plays a functional role in the tumor promoting effects of myeloid cells, and may represent a novel target for cancer therapy. | Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.
Luger D, Yang YA, Raviv A, Weinberg D, Banerjee S, Lee MJ, Trepel J, Yang L, Wakefield LM., Free PMC Article | 07/26/2014 |
| STN produced significant antitumor effects in a mouse xenograft model of CD79A/B-mutated DLBCL. | Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, Lenz P, Waters NJ, Schuler W, Dörken B, Yao YM, Warmuth M, Lenz G, Stegmeier F. | 07/16/2011 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| CD79a may be helpful marker in the differential diagnosis of classical Hodgkin's lymphoma and primary mediastinal B-cell lymphoma | BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
Hoeller S, Zihler D, Zlobec I, Obermann EC, Pileri SA, Dirnhofer S, Tzankov A. | 07/26/2010 |
| we determined the significance of loss or downregulation of CD79a, overexpression of cyclinD1, and c-maf expression in bone marrow specimens with plasma cell myeloma | Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis.
Tanaka T, Ichimura K, Sato Y, Takata K, Morito T, Tamura M, Kondo E, Ohara N, Yanai H, Sakai M, Takahashi S, Yoshino T. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (3) articlesNew genetic associations detected in a host response study to hepatitis B vaccine.
Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium. Common genetic variants in candidate genes and risk of familial lymphoid malignancies.
Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR. | 08/12/2009 |
| Median survival time of cytoplasmic CD79 alpha positive group was shorter than that of cytCD79a negative group in acute myeloid leukemia. | [Prognostic effect of cytoplasmic CD79a expression in acute myeloid leukemia with t(8;21)].
Chung HJ, Chi HS, Cho YU, Lee EH, Jang S, Park CJ, Seo EJ. | 01/21/2010 |
| Ig-alpha was phosphorylated in all myeloma IgG BCR isolates, the 31-kD variant being phosphorylated most frequently. It was not phosphorylated in normal control B cells. | Signaling status of IgG B cell receptor (IgG BCR) is indicative for an activated state of circulating B cells in multiple myeloma.
Ilić V, Milosević-Jovcić N, Petrović S, Marković D, Bila J, Bosković D, Stefanović G, Marković O, Glibetić M. | 01/21/2010 |
| Anti-CD79b antibodies downregulated surface B-cell receptor and were trafficked to the lysosomal-like major histocompatibility complex class II-positive compartment of a mouse xenograft model of non-Hodgkin lymphoma. | Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C, Hongo JA, Gogineni A, Cole MJ, Vandlen R, Stephan JP, Young J, Chang W, Scales SJ, Ross S, Eaton D, Ebens A. | 01/21/2010 |
| Results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis. | PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, Liso A, Diverio D, Lo-Coco F, Falini B. | 01/21/2010 |
| B cell-restricted mb-1 gene: expression, function, and lineage infidelity. Review. | B cell-restricted human mb-1 gene: expression, function, and lineage infidelity.
Herren B, Burrows PD. | 01/21/2010 |
| FISH findings indicate that CD79a, despite its specificity for B-cell differentiation, represented the aberrant presence of a B-cell antigen in leukemias of distinct myeloid linage. | CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
Kozlov I, Beason K, Yu C, Hughson M. | 01/21/2010 |
| lower levels of B-cell receptor surface expression observed in chronic lymphocytic leukemia are accounted for by an impaired glycosylation and folding of the mu and CD79a chains. | Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains.
Vuillier F, Dumas G, Magnac C, Prevost MC, Lalanne AI, Oppezzo P, Melanitou E, Dighiero G, Payelle-Brogard B. | 01/21/2010 |